MedTrace Logo

Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty

NCT01102491 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2012-06-08

Study results available
· View outcomes & findings →

Summary

The purposes of this study are to document the antiemetic efficacy of multimodal antiemetic protocol in patient after Total Knee Arthroplasty using regional anesthesia, midazolam \& propofol, hydration \& oxygen supplement, preemptive \& multimodal contemporary pain management and to determine whether Ramosetron prophylaxis would provide additional antiemetic effect on this protocol. We hypothesized that the incidence of Postoperative nausea and vomiting during multimodal antiemetic protocol would be lower than Apfel's expected postoperative nausea and vomiting incidence. It was also hypothesized that Ramosetron prophylaxis would provide additional antiemetic effect.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

Ramosetron

ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • T K Kim, MD,PhD · Joint Recontruction Center, Seoul National University Bundang hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
86 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-02-28
Completion
2010-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01102491 on ClinicalTrials.gov